Vipul Jairath

Vipul oversees the global Medical R&D initiatives and services. In conjunction with the executive team and senior medical advisors, he assumes overall responsibility for research strategy, as well as performance of the organization’s Medical R&D services including medical operations, medical imaging, precision medicine, medical writing, medical monitoring, medical/biostatics advisory collaborations and IBD fellowships. He also provides medical oversight for the design of clinical trials, protocol development and imaging R&D endpoints. Vipul was previously VP Medical Research & Development (2019-2021) and Director of Academic Research and Development (2016-19).


Dr Jairath obtained his BSc (Pharmacology) and Medical Degree from the University of Leeds (UK), DPhil (PhD) in Clinical Medicine from the University of Oxford and post-graduate diploma in Clinical Trials from the London School of Hygiene and Tropical Medicine. He is Professor of Medicine at the Schulich School of Medicine and Dentistry, and holder of the John and Susan McDonald Endowed Chair in Inflammatory Bowel Disease (IBD) at Western University.

His specialist clinical training in Gastroenterology was completed in London and Oxford, and he holds specialist certification in both Ontario and the UK. Prior to moving to Western in 2016, he was a National Institute for Health Research Clinical Trials Fellow at the Oxford Clinical Trials Research Unit and Consultant Gastroenterologist at Oxford University hospitals.

He is a practising gastroenterologist and specialist in inflammatory bowel disease, and his research interests in clinical therapeutics for IBD include design of clinical trials, development and validation of outcome measures for use in clinical trials, patient reported outcome measures and prediction modelling for response to therapy.


Vipul has driven the development and validation of several novel indices for use in IBD clinical trials, like the UC-100 and the novel patient reported outcome measures, SIQ-UC and SIQ-CD. In addition, he was instrumental to the delivery of the REACT2 trial and to the design of the VERDICT trial, both of which are important clinical practice questions for patients with Crohn’s Disease and Ulcerative Colitis, respectively.


“We are what we repeatedly do. Excellence, then, is not an act, but a habit.” — Aristotle

William Sandborn

William has been a medical consultant at Alimentiv since 2011. His expertise in inflammatory bowel disease (IBD) clinical trial design and execution, and related regulatory issues has been instrumental in Alimentiv’s growth.



From 1993-2010, Dr. Sandborn was on the faculty of the Mayo Clinic, rising to Professor of Medicine, Vice Chairman of the Division of Gastroenterology and Hepatology, and Associate Dean of Research for Intellectual Property and Industry Relations. In 2011, he became a tenured Professor of Medicine at the University of California San Diego and Director of the IBD Center, and Chief of the Division of Gastroenterology for the UC San Diego Health System. He is Vice Chair for Clinical Operations for the Department of Medicine and a member of the UC San Diego Health Physicians Group Board (which oversees the clinical practice for the entire UC San Diego Health System).



Dr. Sandborn has achieved an h-index of 135. He has published over 781 peer reviewed articles including articles in the New England Journal of Medicine, Nature, Lancet, JAMA, Annals of Internal Medicine and Gastroenterology. He is also a member of the editorial board for the New England Journal of Medicine.


In 2019, he was awarded the Sherman Prize for his work in IBD.



“Time may not define your dreams, but how you spend your time will determine whether you reach your dreams. The only way to control the outcome of your own life is to thoughtfully determine your own priorities and goals, and then to realistically allocate your time in a way that will allow you to achieve your goals.”

Brian G. Feagan

Dr. Feagan completed a medical degree at the University of Western Ontario in London, Ontario, Canada.

His postdoctoral training included residency in the Department of Medicine and a fellowship in Gastroenterology at the University of Western Ontario. A Fellow of the Royal College of Physicians and Surgeons of Canada, Dr. Feagan holds membership in the Canadian and American Association of Gastroenterology, the American College of Gastroenterology, the College of Physicians and Surgeons of Ontario, Crohn’s and Colitis Canada (CCC) and European Crohn’s and Colitis Organization (ECCO). He has authored over 300 articles and book chapters and has given over 90 invited presentations at national and international scientific meetings. In 1997, Dr. Feagan became Director of Alimentiv Clinical Trials at the Alimentiv Research Institute, University of Western Ontario. His research efforts focus on the design and implementation of randomized controlled trials of therapy for inflammatory bowel disease. He has been the principal investigator on numerous large-scale randomized clinical trials.